Download Now - The Burrill Report

SEPTEMBER STATISTICSThe Burrill ReportSeptember 2012 M&AACQUIRER COUNTRY TARGET COUNTRY DEAL VALUE(USD M)Valeant Pharmaceuticals Canada MedicisPharmaceuticalASSETSTAGEPRINCIPAL FOCUSUnited States 2,600.0 Marketed DermatologyBASF Germany Becker Underwood United States 1,020.0 Crop protectionMedtronic United States China KanghuiHoldingsChina 816.0 Orthopedic devicesSyngenta Switzerland Devgen Belgium 523.0 AgbiotechDanaher United States Iris International United States 338.0 DiagnosticsConvaTec United States 108 MedicalHoldingsPerrigo Company United States Sergeant’s Pet CareProductsThoma Bravo United States MediwareInformationSystemsBayer Healthcare Germany Teva’s animal drugunitUnited States 321.0 Medical suppliesUnited States 285.0 OTC pet careUnited States 195.0 Clinical trials softwareIsrael 145.0 Animal healthValeant Pharmaceuticals Canada QLT’s Visudyne Canada 132.5 Marketed Eye careBGI China CompleteGenomicsSyngenta Switzerland PasteuriaBioscienceUnited States 117.6 Next gen sequencingUnited States 113.0 BiopesticidesMallinckrodt (Covidien) Ireland CNS Therapeutics United States 100.0 Marketed NeurologyMeda Sweden JazzPharmaceuticals’unitBeecken Petty O’Keefe & Co United States PSS World MedicalunitKingbird Investment Cayman Islands China NuokangBio-PharmaceuticalUnited States 95.0 Marketed Women’s healthUnited States 68.0 Dental supply/serviceChina 43.4 PharmaceuticalsTeva Pharmaceuticals Israel NeuroSearch assets Denmark 35.7 Huntington’s diseaseBionomics Australia EclipseTherapeuticsAmpliPhi Biosciences United States Special PhageServicesPristine Solutions United States Eaton ScientificSystemsUnited States 10.0 Preclinical Cancer stem cellsAustralia 4.4 Antibacterial drugsUnited States 3.8 Neurology; drugdeliveryAccelPath United States DigiPath Solutions United States 2.4 Digital telepathologyRohto Pharmaceutical Japan Agera Laboratories(Fibrocell)United States 1.0 DermatologyCLC bio Germany Molegro Denmark N/A BioinformaticsSias Switzerland Xiril Switzerland N/A Tools/TechnologyMedivir Sweden Novadex PharmaassetsLink Healthcare Australia Equity PharmaHoldingsSweden N/A Preclinical AntiviralsSouth Africa N/A GenericsMitsubishi Tanabe Pharma Japan Bipha Corp Japan N/A PharmaceuticalsDRI Capital Managed Fund United States Biogen IdecBenlysta royaltiesSynthetic Genomics United States Febit HoldingpatentsUnited States N/A Royalty rightsGermany N/A Synthetic genomics(continued) ❱❱November 2012 34